Baseline characteristics of the study population
| Characteristics | All | RVEF <25% | RVEF ≥25% | p-value |
| Subjects n | 100 | 50 | 50 | |
| Demographics | ||||
| Age years | 57.2±18.6 | 58.0±18.8 | 56.5±18.7 | 0.683 |
| Females/males n | 61/39 | 26/24 | 35/15 | 0.065 |
| Body mass index kg·m−2 | 26.9±6.4 | 26.6±6.6 | 27.2±6.2 | 0.631 |
| PAH group | ||||
| Idiopathic | 79 (79) | 39 (78) | 40 (80) | 0.806 |
| Familial | 4 (4) | 2 (4) | 2 (4) | 0.967 |
| Anorexigen-associated | 17 (17) | 9 (18) | 8 (16) | 0.790 |
| NYHA FC | ||||
| I | 3 (3) | 3 (6) | 0 (0) | 0.420 |
| II | 41 (41) | 17 (34) | 24 (48) | |
| III | 51 (51) | 26 (52) | 25 (50) | |
| IV | 5 (5) | 4 (8) | 1 (2) | |
| 6-min walking distance m | 336±144 | 335±116 | 337±170 | 0.962 |
| ERNA % | ||||
| RVEF | 26.6±8.9 | 18.1±4.3 | 32.4±5.2 | <0.001 |
| LVEF | 58.9±9.4 | 55.4±8.7 | 62.3±8.8 | <0.001 |
| Echocardiography | ||||
| TAPSE mm | 17.4±5.1 | 16.2±5.0 | 18.8±5.0 | 0.018 |
| TAPSV cm·s−1 | 10.6±2.6 | 10.4±3.0 | 11.0±2.1 | 0.336 |
| Biochemistry | ||||
| NT-proBNP plasma levels pg·mL−1 | 2067±2110 | 2582±2111 | 1411±1964 | 0.050 |
| eGFR mL·min−1 | 76.8±28.8 | 76.6±30.3 | 76.9±27.5 | 0.960 |
| Haemodynamic data | ||||
| Right atrial pressure mmHg | 7.8±5.2 | 8.7±5.8 | 6.7±4.3 | 0.061 |
| Mean PAP mmHg | 43.6±12.6 | 44.8±12.2 | 42.4±13.1 | 0.349 |
| PVR dyn·s·cm−5 | 788±611 | 886±714 | 698±488 | 0.141 |
| Cardiac index L·min−1·m−2 | 2.3±0.6 | 2.2±0.6 | 2.5±0.6 | 0.020 |
| Medication use | ||||
| Endothelin receptor antagonist | 47 (47) | 25 (50) | 22 (44) | 0.548 |
| Phosphodiesterase-5 inhibitor | 27 (27) | 12 (24) | 15 (30) | 0.499 |
| Intravenous epoprostenol | 9 (9) | 7 (14) | 2 (4) | 0.081 |
| Calcium antagonists | 2 (2) | 2 (4) | 0 (0) | 0.153 |